Management of Tuberculous Iritis in HIV‑Negative Patients

Standard Anti‑Tuberculosis Regimen (British Thoracic Society)

• The British Thoracic Society recommends that ocular tuberculosis be treated with the same 6‑month short‑course regimen used for pulmonary disease—2 months of rifampicin, isoniazid, pyrazinamide and ethambutol (HRZE) followed by 4 months of rifampicin and isoniazid (HR)【1】【2】【3】.
• Initial phase (2 months): Daily HRZE for 8 weeks is the standard schedule【1】【2】. Ethambutol may be omitted in patients with low risk of isoniazid resistance (HIV‑negative, no known contact with drug‑resistant TB)【1】【2】. An alternative dosing scheme (daily for ≥2 weeks, then twice‑weekly for 6 weeks) is acceptable【1】.
• Continuation phase (4 months): Daily (or 2–3 times weekly) rifampicin + isoniazid for 4 months completes therapy, giving a total duration of 6 months【1】【2】【3】.

Strength of evidence: Guideline recommendation based on consensus and clinical outcome data (high‑level evidence within the British Thoracic Society guidelines).

Adjunctive Systemic Corticosteroid Therapy (British Thoracic Society)

• For tuberculous uveitis, the British Thoracic Society supports adding systemic corticosteroids to the anti‑TB regimen; high‑dose prednisone (≈60 mg/day initially, tapered over several weeks) has shown clear benefit in other extrapulmonary TB forms such as pericarditis【2】【3】.

Strength of evidence: Guideline recommendation with moderate‑to‑high confidence derived from extrapolation of pericarditis data.

Pyridoxine (Vitamin B6) Supplementation

• Routine daily pyridoxine is not required for HIV‑negative patients receiving standard therapy【1】【2】.
• Pyridoxine should be given to patients at increased risk of peripheral neuropathy (e.g., malnutrition, alcohol use)【1】.

Strength of evidence: Guideline recommendation (low‑risk population).

Extended Treatment Scenarios (British Thoracic Society)

• If pyrazinamide cannot be used in the initial phase, extend the total treatment duration to 9 months and retain ethambutol for the first 2 months【1】【2】.

Strength of evidence: Guideline recommendation (moderate confidence).

Monitoring and Follow‑Up

• Obtain baseline mycobacterial culture and drug‑susceptibility testing whenever feasible【1】.
• When a culture is positive but susceptibility results are pending after 2 months, continue pyrazinamide (and ethambutol) until full susceptibility is confirmed【1】.
• Conduct monthly clinical reviews to assess adherence and detect medication adverse effects【4】.

Strength of evidence: CDC/MMWR recommendation (moderate evidence).

Avoiding Drug Resistance (Clinical Infectious Diseases)

• Never add a single drug to a failing regimen, as this creates functional monotherapy and promotes resistance【5】.
• If resistance is suspected, add at least two drugs to which the organism is likely susceptible【5】.

Strength of evidence: Expert consensus and observational data (moderate evidence).